Overview

  • Product nameAnti-Lamin A antibody [133A2]
    See all Lamin A primary antibodies
  • Description
    Mouse monoclonal [133A2] to Lamin A
  • SpecificityReacts against lamin A exclusively (the antibody was raised against the carboxy-terminus of 98 amino acids present in lamin A and absent from lamin C. As a result, this antibody recognizes lamin A but not lamin C; See Machiels et al 1997). Lamins do not appear to be universally distributed among different cell and tissue types. ab8980 has been tested in testis parenchyma and testicular germ cell tumours (See Machiels et al 1997). Other cell/tissue types have not been tested.
  • Tested applicationsSuitable for: Flow Cyt, ICC, IHC-Fr, WB, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Cow, Dog, Human, Monkey
  • Immunogen

    Recombinant fragment corresponding to Human Lamin A (C terminal). Around aa 598 to 611.

  • EpitopeBetween residues 598-611
  • Positive control
    • This antibody gave a positive signal in the following cell types: HeLa.

Properties

Applications

Our Abpromise guarantee covers the use of ab8980 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt 1/100 - 1/200. ab18392-Mouse monoclonal IgG3, is suitable for use as an isotype control with this antibody.
ICC 1/100 - 1/200.
IHC-Fr 1/100 - 1/200.
WB 1/100 - 1/1000. Predicted molecular weight: 74 kDa. PubMed: 92745311/1000. Predicted molecular weight: 74 kDa.
IHC-P 1/100 - 1/200.
ICC/IF Use a concentration of 1 µg/ml.

Target

  • FunctionLamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin. Lamin A and C are present in equal amounts in the lamina of mammals. Play an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics.
    Prelamin-A/C can accelerate smooth muscle cell senescence. It acts to disrupt mitosis and induce DNA damage in vascular smooth muscle cells (VSMCs), leading to mitotic failure, genomic instability, and premature senescence.
  • Tissue specificityIn the arteries, prelamin-A/C accumulation is not observed in young healthy vessels but is prevalent in medial vascular smooth muscle celle (VSMCs) from aged individuals and in atherosclerotic lesions, where it often colocalizes with senescent and degenerate VSMCs. Prelamin-A/C expression increases with age and disease. In normal aging, the accumulation of prelamin-A/C is caused in part by the down-regulation of ZMPSTE24/FACE1 in response to oxidative stress.
  • Involvement in diseaseDefects in LMNA are the cause of Emery-Dreifuss muscular dystrophy type 2 (EDMD2) [MIM:181350]. A degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.
    Defects in LMNA are the cause of cardiomyopathy dilated type 1A (CMD1A) [MIM:115200]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
    Defects in LMNA are the cause of familial partial lipodystrophy type 2 (FPLD2) [MIM:151660]; also known as familial partial lipodystrophy Dunnigan type. A disorder characterized by the loss of subcutaneous adipose tissue in the lower parts of the body (limbs, buttocks, trunk). It is accompanied by an accumulation of adipose tissue in the face and neck causing a double chin, fat neck, or cushingoid appearance. Adipose tissue may also accumulate in the axillae, back, labia majora, and intraabdominal region. Affected patients are insulin-resistant and may develop glucose intolerance and diabetes mellitus after age 20 years, hypertriglyceridemia, and low levels of high density lipoprotein cholesterol.
    Defects in LMNA are the cause of limb-girdle muscular dystrophy type 1B (LGMD1B) [MIM:159001]. LGMD1B is an autosomal dominant degenerative myopathy with age-related atrioventricular cardiac conduction disturbances, dilated cardiomyopathy, and the absence of early contractures. LGMD1B is characterized by slowly progressive skeletal muscle weakness of the hip and shoulder girdles. Muscle biopsy shows mild dystrophic changes.
    Defects in LMNA are the cause of Charcot-Marie-Tooth disease type 2B1 (CMT2B1) [MIM:605588]. CMT2B1 is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2B1 inheritance is autosomal recessive.
    Defects in LMNA are the cause of Hutchinson-Gilford progeria syndrome (HGPS) [MIM:176670]. HGPS is a rare genetic disorder characterized by features reminiscent of marked premature aging. Note=HGPS is caused by the toxic accumulation of a mutant form of lamin-A/C. This mutant protein, called progerin, acts to deregulate mitosis and DNA damage signaling, leading to premature cell death and senescence. Progerin lacks the conserved ZMPSTE24/FACE1 cleavage site and therefore remains permanently farnesylated. Thus, although it can enter the nucleus and associate with the nuclear envelope, it cannot incorporate normally into the nuclear lamina.
    Defects in LMNA are the cause of cardiomyopathy dilated with hypergonadotropic hypogonadism (CMDHH) [MIM:212112]. A disorder characterized by the association of genital anomalies, hypergonadotropic hypogonadism and dilated cardiomyopathy. Patients can present other variable clinical manifestations including mental retardation, skeletal anomalies, scleroderma-like skin, graying and thinning of hair, osteoporosis. Dilated cardiomyopathy is characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia.
    Defects in LMNA are the cause of mandibuloacral dysplasia with type A lipodystrophy (MADA) [MIM:248370]. A disorder characterized by mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, progeroide appearance, partial alopecia, soft tissue calcinosis, joint contractures, and partial lipodystrophy with loss of subcutaneous fat from the extremities. Adipose tissue in the face, neck and trunk is normal or increased.
    Defects in LMNA are a cause of lethal tight skin contracture syndrome (LTSCS) [MIM:275210]; also known as restrictive dermopathy (RD). Lethal tight skin contracture syndrome is a rare disorder mainly characterized by intrauterine growth retardation, tight and rigid skin with erosions, prominent superficial vasculature and epidermal hyperkeratosis, facial features (small mouth, small pinched nose and micrognathia), sparse/absent eyelashes and eyebrows, mineralization defects of the skull, thin dysplastic clavicles, pulmonary hypoplasia, multiple joint contractures and an early neonatal lethal course. Liveborn children usually die within the first week of life. The overall prevalence of consanguineous cases suggested an autosomal recessive inheritance.
    Defects in LMNA are the cause of heart-hand syndrome Slovenian type (HHS-Slovenian) [MIM:610140]. Heart-hand syndrome (HHS) is a clinically and genetically heterogeneous disorder characterized by the co-occurrence of a congenital cardiac disease and limb malformations.
    Defects in LMNA are the cause of muscular dystrophy congenital LMNA-related (CMD-LMNA) [MIM:613205]. It is a form of congenital muscular dystrophy. Patients present at birth, or within the first few months of life, with hypotonia, muscle weakness and often with joint contractures.
  • Sequence similaritiesBelongs to the intermediate filament family.
  • Post-translational
    modifications
    Increased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations.
    Proteolytic cleavage of the C-terminal of 18 residues of prelamin-A/C results in the production of lamin-A/C. The prelamin-A/C maturation pathway includes farnesylation of CAAX motif, ZMPSTE24/FACE1 mediated cleavage of the last three amino acids, methylation of the C-terminal cysteine and endoproteolytic removal of the last 15 C-terminal amino acids. Proteolytic cleavage requires prior farnesylation and methylation, and absence of these blocks cleavage.
    Sumoylation is necessary for the localization to the nuclear envelope.
    Farnesylation of prelamin-A/C facilitates nuclear envelope targeting.
  • Cellular localizationNucleus. Nucleus envelope. Farnesylation of prelamin-A/C facilitates nuclear envelope targeting and subsequent cleaveage by ZMPSTE24/FACE1 to remove the farnesyl group produces mature lamin-A/C, which can then be inserted into the nuclear lamina. EMD is required for proper localization of non-farnesylated prelamin-A/C.
  • Information by UniProt
  • Database links
  • Alternative names
    • 70 kDa lamin antibody
    • CDDC antibody
    • EMD2 antibody
    • FPL antibody
    • FPLD antibody
    • HGPS antibody
    • IDC antibody
    • LAMIN A antibody
    • lamin A/C antibody
    • LAMIN C antibody
    • Lamin-A/C antibody
    • LDP1 antibody
    • LFP antibody
    • LMN 1 antibody
    • LMN A antibody
    • LMN C antibody
    • LMNA antibody
    • LMNA_HUMAN antibody
    • LMNC antibody
    • PRO1 antibody
    • Renal carcinoma antigen NY-REN-32 antibody
    see all

Anti-Lamin A antibody [133A2] images

  • These images show HeLa cells stained with Laminin A antibody - ab8980 (green) and with DAPI (blue). The pictures were kindly supplied as part of the review submitted by Dr Josef Gotzmann at Medical University of Vienna, Austria.
  • ICC/IF image of ab8980 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum (ab7481) / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab8980 at 1µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- mouse (ab96879) IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • All lanes : Anti-Lamin A antibody [133A2] (ab8980) at 1/1000 dilution

    Lane 1 : Mouse Heart cell lysate - nuclear fraction
    Lane 2 : Mouse Heart cell lysate - non-nuclear fraction

    Lysates/proteins at 20 µg per lane.

    Secondary
    An HRP-conjugated Goat polyclonal at 1/5000 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 74 kDa
    Observed band size : 75 kDa (why is the actual band size different from the predicted?)

    This image is courtesy of an anonymous Abreview

    Blocking Step: 5% Milk for 1 hour at room temperature

    See Abreview

  • ab8980 staining of Lamin A in adult mouse liver sections. Formaldehyde-fixed paraffin-embedded sections of mouse liver tissue were incubated with ab8980 (1/2500) fo 2 hours. Antigen retrieval was performed by heat induction in citrate buffer pH 6.0 (ab64214). Please see accompanying abreview for additional information.

    See Abreview

  • Immunohistochemistry on paraffin section of human colon.

  • Immunohistochemistry on frozen sections of human colon showing nuclear lamina staining in epithelial and connective tissue cells.

  • Overlay histogram showing HeLa cells stained with ab8980 (red line). The cells were fixed with methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab8980, 1/100 dilution) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG3 [MG3-35] (2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a decreased signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween used under the same conditions.

  • Immunocytochemical staining of fiboblasts showing nuclear lamina

References for Anti-Lamin A antibody [133A2] (ab8980)

This product has been referenced in:
  • Elkhatib R  et al. Nuclear envelope remodelling during human spermiogenesis involves somatic B-type lamins and a spermatid-specific B3 lamin isoform. Mol Hum Reprod 21:225-36 (2015). Read more (PubMed: 25477337) »
  • Dvash E  et al. Leukotriene C4 is the major trigger of stress-induced oxidative DNA damage. Nat Commun 6:10112 (2015). IHC ; Mouse . Read more (PubMed: 26656251) »

See all 22 Publications for this product

Product Wall

We have not previously tested whether this antibody stains progerin.

The epitope of ab8980 corresponds to amino acids 598-611.According to uniprot (http://www.uniprot.org/uniprot/P02545), progerin lacks amino acids 607-656.

There is t...

Read More
Application Western blot
Loading amount 15 µg
Gel Running Conditions Non-reduced Denaturing (8%)
Sample Mouse Cell lysate - whole cell (Mice brain tissue)
Specification Mice brain tissue
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 24°C
Username

Abcam user community

Verified customer

Submitted Apr 15 2014

Application Immunocytochemistry/ Immunofluorescence
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 24°C
Sample Mouse Cell (Neuronal Progenitor cell line)
Specification Neuronal Progenitor cell line
Permeabilization Yes - PBS 1%BSA 0,1% Saponine
Fixative Paraformaldehyde
Username

Abcam user community

Verified customer

Submitted Apr 03 2014

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Rat Cell lysate - nuclear (H9C2 cell)
Loading amount 20 µg
Specification H9C2 cell
Gel Running Conditions Reduced Denaturing
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: rt°C
Username

Abcam user community

Verified customer

Submitted Feb 15 2013

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Rat Cell (h9c2)
Specification h9c2
Fixative Paraformaldehyde
Permeabilization Yes - 1% triton x100
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: rt°C
Username

Abcam user community

Verified customer

Submitted Feb 15 2013

Thanks! I will look forward to hearing from you soon.

Thank you for your email.

"In my blot with lysates from mouse , I have proteins from extraction with RIPA-N and with fractionned extraction. And no band." Does this mean you have performed cell lysis with RIPA buffer also and there w...

Read More

Thank you for your email. I am sorry to hear that you have been experiencing problems with this antibody.

The antibody has been characterized with mouse lysates and found to be specific to mouse protein, which is why we are selling this as mou...

Read More

Thank you for your enquiry.

Below is a selection of antibodies that are suitable for detecting the plasma membrane and nuclear envelope. They all work in western blot and I would review the datasheets to confirm which species they are tested...

Read More

We usually recommend overnight incubation as thisallows antibodies of lower titer or affinity to be used by simply allowing more time for the antibodies to bind. Also, regardless of the antibody’s titer or affinity for its target, once the tissue...

Read More

1-10 of 36 Abreviews or Q&A

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"